|
Jan 8
|
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
|
|
Jan 4
|
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
|
|
Jan 3
|
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
|
|
Dec 21
|
Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
|
|
Dec 6
|
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
|
|
Dec 4
|
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 28
|
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
|
|
Nov 20
|
Cardio Diagnostics Establishes A New Partnership To Facilitate Global Footprint And Expansion Beyond North America With India-Based Aimil Ltd.
|
|
Nov 20
|
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
|
|
Nov 7
|
Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
|
|
Apr 26
|
Juniper Research Awards Cardio Diagnostics Holdings, Inc Future Digital Award for Best Digital Diagnostics Solution
|